Teva bails from OncoGenex custirsen deal; paying $27m
This article was originally published in Scrip
Teva will start 2015 by returning the rights to OncoGenex for custirsen, which failed a Phase III metastatic castrate-resistant prostate cancer study this past spring.
You may also be interested in...
Custirsen, the lead drug candidate from OncoGenex, failed in a second Phase III clinical trial – a trial that may have represented the company's last, best hope of success.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.